Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Reata Pharmaceuticals, Inc. Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc. September 21, 2023 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals Announces Approval of Prior Approval Supplement for SKYCLARYS® (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich’s Ataxia June 27, 2023 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS® (Omaveloxlone) NDA Prior Approval Supplement June 15, 2023 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer June 13, 2023 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference June 06, 2023 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals, Inc. Announces First Quarter 2023 Financial Results and Provides an Update on Operational Progress and Clinical Development Programs May 10, 2023 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals, Inc. to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10, 2023 May 02, 2023 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals Announces Participation in the Barclays Global Healthcare Conference March 06, 2023 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s Ataxia February 28, 2023 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals Announces Participation in the Guggenheim 2022 Immunology and Neurology Conference and the Stifel 2022 Healthcare Conference November 10, 2022 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs November 08, 2022 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals, Inc. to Report Third Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on November 8, 2022 October 31, 2022 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals Announces Presentations at the International Congress for Ataxia Research 2022 October 20, 2022 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals Announces that the FDA Does Not Plan to Hold an Advisory Committee Meeting to Discuss the NDA for Omaveloxolone for Friedreich’s Ataxia October 13, 2022 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals Announces Participation in the Citi 17th Annual BioPharma Conference September 06, 2022 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich’s Ataxia August 09, 2022 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs August 08, 2022 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals, Inc. to Report Second Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on August 8, 2022 August 01, 2022 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Announces the Appointment of Steven W. Ryder, M.D. to its Board of Directors July 11, 2022 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals Announces FDA Filing Acceptance and Priority Review Designation for the NDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia May 26, 2022 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs May 10, 2022 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals, Inc. to Report First Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on May 10, 2022 May 02, 2022 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals Completes Rolling Submission of New Drug Application for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia March 31, 2022 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results and Provides an Update on Clinical Development Programs February 28, 2022 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals Receives Complete Response Letter From The FDA for Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome February 25, 2022 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals, Inc. To Report Fourth Quarter and Full Year 2021 Financial Results and To Provide an Update on Development Programs on February 28, 2022 February 18, 2022 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals Initiates Rolling Submission of New Drug Application with U.S. FDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia January 31, 2022 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals Announces Outcome of FDA Advisory Committee Meeting of Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome December 08, 2021 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Discuss Bardoxolone for the Treatment of Patients With Chronic Kidney Disease Caused by Alport Syndrome December 08, 2021 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Reata Pharmaceuticals Receives Fast Track Designation From the FDA for Omaveloxolone for the Treatment of Friedreich’s Ataxia November 18, 2021 From Reata Pharmaceuticals, Inc. Via Business Wire Tickers RETA Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
